🇺🇸 TAMIBAROTENE in United States

23 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Central Nervous System Leukaemia — 4 reports (17.39%)
  2. Leukaemia Recurrent — 4 reports (17.39%)
  3. Acute Promyelocytic Leukaemia — 3 reports (13.04%)
  4. Death — 2 reports (8.7%)
  5. Drug Ineffective — 2 reports (8.7%)
  6. Drug Resistance — 2 reports (8.7%)
  7. Haemorrhage — 2 reports (8.7%)
  8. Pneumonia — 2 reports (8.7%)
  9. Abdominal Pain Upper — 1 report (4.35%)
  10. Acute Promyelocytic Leukaemia Differentiation Syndrome — 1 report (4.35%)

Source database →

TAMIBAROTENE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is TAMIBAROTENE approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for TAMIBAROTENE in United States?

Marketing authorisation holder not available in our data.